The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2 Academic Article uri icon

Overview

MeSH Major

  • Antithrombins
  • Atrial Fibrillation
  • Dabigatran
  • Fibrinolytic Agents
  • Registries
  • Stroke

abstract

  • The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701).

authors

publication date

  • February 21, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2016.11.061

PubMed ID

  • 28209218

Additional Document Info

start page

  • 777

end page

  • 785

volume

  • 69

number

  • 7